A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

Affiliations

Yunxin Chen: Department of Haematology, Singapore General Hospital
Sathish Kumar Gopalakrishnan: Department of Haematology, Singapore General Hospital
Melissa Ooi: Department of Haematology, National University Hospital
Rehena Sultana: Centre for Quantitative Medicine, DUKE-NUS Medical School
Li Hui Lim: Department of Haematology, Singapore General Hospital
Nicholas Grigoropoulos: Department of Haematology, Singapore General Hospital
Shin Yeu Ong: Department of Haematology, Singapore General Hospital
Mingge Xu: Department of Haematology, National University Hospital
SGHMM1 Investigators
Wee Joo Chng: Department of Haematology, National University Hospital
Yeow Tee Goh: Department of Haematology, Singapore General Hospital
Chandramouli Nagarajan: Department of Haematology, Singapore General Hospital

Abstract

No abstracts available.

ISSN: 2044-5385 (Online)
Publisher: Nature Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.nature.com/bcj/index.html